Peptide-receptor radionuclide therapy with radiolabelled somatostatin analogues is a successful new treatment modality for patients with neuroendocrine tumours. Usually, 90yttrium (90Y)-coupled or 177lutetium (177Lu)-coupled somatostatin analogues are used, but a new study claims that combining the two radiopharmaceuticals results in improved overall survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
10 July 2012
In the version of this article initially published online and in print there was a mistake in the use of 177Lu-DOTATATE instead of 177Lu-DOTATOC in the first sentence of the third paragraph. The correct sentence should have read "Villard et al.1 compared the efficacy of PRRT with 90Y-DOTATOC to that of PRRT with combined 90Y-DOTATOC and 177Lu-DOTATOC in a large series of patients with metastatic neuroendocrine cancer." The error has been corrected for the HTML and PDF versions of the article.
References
Villard, L. et al. Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol. 30, 1100–1106 (2012).
Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124–2130 (2008).
Imhof, A. et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29, 2416–2423 (2011).
Bushnell, D. L. Jr et al. 90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 28, 1652–1659 (2010).
Khan, S. et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J. Nucl. Med. 52, 1361–1368 (2011).
Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
de Jong, M., Breeman, W. A., Valkema, R., Bernard, B. F. & Krenning, E. P. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J. Nucl. Med. 46 (Suppl. 1), 13S–17S (2005).
O'Donoghue, J. A., Bardiès, M. & Wheldon, T. E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 36, 1902–1909 (1995).
Kunikowska, J. et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging 38, 1788–1797 (2011).
De Kruijk, J. R., Leffers, P., Meerhoff, S., Rutten, J. & Twijnstra, A. Effectiveness of bed rest after mild traumatic brain injury: a randomised trial of no versus six days of bed rest. J. Neurol. Neurosurg. Psychiatry 73, 167–172 (2002).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares an association with the following company: Advanced Accelerator Applications (stock holder/director).
Rights and permissions
About this article
Cite this article
Kwekkeboom, D. Neuroendocrine cancer—are two radionuclides better than one?. Nat Rev Endocrinol 8, 326–328 (2012). https://doi.org/10.1038/nrendo.2012.64
Published:
Issue date:
DOI: https://doi.org/10.1038/nrendo.2012.64
This article is cited by
-
Correction: Therapy: Neuroendocrine cancer—are two radionuclides better than one?
Nature Reviews Endocrinology (2012)
